CYCN - Cyclerion Therapeutics Inc Stock Price, Fair Value and News

2.93USD-0.11 (-3.62%)Market Closed

Market Summary

USD2.93-0.11

Market Closed

-3.62%

CYCN Stock Price

View Fullscreen

CYCN RSI Chart

CYCN Valuation

Market Cap

7.9M

Price/Earnings (Trailing)

-1.51

Price/Sales (Trailing)

1.02

Price/Free Cashflow

-0.37

CYCN Price/Sales (Trailing)

CYCN Profitability

Return on Equity

-46.62%

Return on Assets

-39.35%

Free Cashflow Yield

-267.55%

CYCN Fundamentals

CYCN Revenue

Revenue (TTM)

8.5M

Rev. Growth (Qtr)

100%

CYCN Earnings

Earnings (TTM)

-5.3M

Earnings Growth (Yr)

76.52%

Earnings Growth (Qtr)

-122.39%

Breaking Down CYCN Revenue

Last 7 days

-16.3%

Last 30 days

-4.9%

Trailing 12 Months

946.4%

How does CYCN drawdown profile look like?

CYCN Financial Health

Current Ratio

3.85

CYCN Investor Care

Shares Dilution (1Y)

12.43%

Diluted EPS (TTM)

-2.63

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	4.6M	1.9M	1.6M	297.0K
2021	2.7M	3.1M	3.5M	3.9M
2020	4.0M	3.4M	2.8M	2.3M
2019	0	0	0	4.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cyclerion Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 01, 2024	graul regina margaret	acquired	-	-	50,000	president
Jan 01, 2024	hecht peter m	acquired	-	-	15,000	-
Dec 01, 2023	hecht peter m	acquired	-	-	15,000	-
Nov 30, 2023	hyman steven	acquired	-	-	20,000	-
Nov 30, 2023	mcguire terrance	acquired	-	-	5,000	-
Nov 30, 2023	desouza errol b	acquired	-	-	50,000	-
Nov 30, 2023	hecht peter m	acquired	-	-	20,000	-
Aug 09, 2023	mcguire terrance	sold	-27.16	3.395	-8.00	-
May 19, 2023	hecht peter m	acquired	1,953,000	8.68	225,000	chief executive officer
Jun 03, 2021	mcguire terrance	bought	289,633	3.12	92,831	-

Which funds bought or sold CYCN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	reduced	-42.04	-59,924	78,692	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-27.00	1,809	-%
Feb 14, 2024	Slate Path Capital LP	unchanged	-	-25,052	1,198,900	0.03%
Feb 14, 2024	TYNDALL CAPITAL PARTNERS L P	added	11.32	45,662	550,837	100.00%
Feb 14, 2024	Royal Bank of Canada	reduced	-63.82	-2,000	1,000	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	1.66	168	104,748	-%
Feb 13, 2024	ACADIAN ASSET MANAGEMENT LLC	sold off	-100	-7,000	-	-%
Feb 13, 2024	MORGAN STANLEY	reduced	-15.19	-478	2,338	-%
Feb 13, 2024	FMR LLC	reduced	-1.03	-13,922	545,545	-%
Feb 13, 2024	MFN Partners Management, LP	unchanged	-	-8,473	567,691	0.02%

Are Funds Buying or Selling CYCN?

Are funds buying CYCN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CYCN

No. of Funds

Unveiling Cyclerion Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	tyndall capital partners l p	6.7%	164,429	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	artal international s.c.a.	5.7%	138,403	SC 13G/A
Jan 22, 2024	slate path capital lp	14.6%	357,880	SC 13G/A
Dec 05, 2023	hecht peter m	26.9%	840,899	SC 13D/A
Sep 05, 2023	tyndall capital partners l p	5.05%	121,638	SC 13G
May 23, 2023	hecht peter m	19.99%	518,464	SC 13D/A
May 12, 2023	hecht peter m	19.99%	10,369,298	SC 13D/A
Apr 03, 2023	hecht peter m	9.2%	4,219,658	SC 13D/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Cyclerion Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	8-K	Current Report
Mar 11, 2024	3	Insider Trading
Mar 05, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report
Jan 26, 2024	4	Insider Trading
Jan 26, 2024	4	Insider Trading
Jan 22, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Cyclerion Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Cyclerion Therapeutics Inc News

Latest updates

Cyclerion Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-100.0%	-	7,564,000	3,782,000	-	306,000	711,000	533,000	348,000	3,000,000	1,566,500	133,000	400,000	749,000	1,014,000	1,206,000	1,398,000	1,628,000
Operating Expenses	-70.2%	1,795,000	6,015,000	-4,330,000	4,518,000	13,739,000	13,695,000	14,871,000	11,633,000	19,176,000	13,457,000	19,357,000	22,180,000	20,421,000	21,603,000	28,067,000	29,414,000	34,682,000
S&GA Expenses	-73.1%	573,000	2,131,000	2,780,000	3,104,000	3,521,000	3,952,000	4,413,000	4,601,000	6,241,000	5,365,000	7,265,000	8,033,000	6,627,000	6,891,000	7,385,000	7,119,000	8,923,000
R&D Expenses	-95.9%	24,000	580,000	-7,110,000	1,414,000	10,218,000	9,743,000	10,458,000	7,032,000	12,054,000	8,092,000	12,092,000	13,703,000	13,794,000	16,825,000	20,682,000	22,295,000	25,759,000
EBITDA Margin	-	-	-	-31.74	-38.89	-30.44	-11.64	-12.98	-21.62	-24.48	-28.01	-32.89	-32.91	-25.81	-21.67	-26.56	-18.63	-17.36
EBT Margin	-	-	-	-31.78	-38.98	-30.87	-11.83	-13.10	-22.04	-24.94	-28.74	-33.89	-33.59	-26.37	-22.17	-27.16	-19.04	-17.70
Net Income	-122.4%	-1,694,000	7,566,000	-7,216,000	-10,496,000	-13,388,000	-12,978,000	-13,998,000	-11,290,000	-16,182,000	-6,954,000	-19,228,000	-18,812,000	-19,534,000	-20,228,000	-26,055,500	-27,317,000	-32,254,000
Net Income Margin	51.2%	-0.62	-1.27	-27.12	-32.81	-27.21	-11.86	-12.28	-15.20	-19.61	-23.83	-	-	-	-	-	-	-
Free Cashflow	77.8%	-1,541,000	-6,935,000	-7,043,000	-9,915,000	-10,818,000	-12,835,000	-8,630,000	-7,958,000	-5,544,000	-14,490,000	-14,076,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.1%	13.00	15.00	10.00	11.00	18.00	25.00	35.00	47.00	59.00	68.00	76.00	100	115	131	128	140	186	210	236	-	-
Current Assets	-18.7%	8.00	10.00	7.00	8.00	15.00	22.00	32.00	43.00	55.00	64.00	73.00	44.00	59.00	70.00	60.00	70.00	101	121	145	1.00	1.00
Cash Equivalents	-16.9%	8.00	9.00	6.00	7.00	13.00	20.00	30.00	41.00	54.00	63.00	70.00	41.00	58.00	67.00	56.00	67.00	103	117	141	-	-
Net PPE	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	7.00	10.00	11.00	12.00	12.00	12.00	13.00	9.00	6.00
Current Liabilities	-10.9%	2.00	2.00	5.00	8.00	8.00	9.00	10.00	9.00	11.00	11.00	11.00	13.00	17.00	16.00	16.00	11.00	18.00	19.00	22.00	17.00	18.00
Shareholder's Equity	-12.3%	11.00	13.00	5.00	4.00	10.00	17.00	25.00	37.00	48.00	56.00	65.00	48.00	59.00	75.00	66.00	82.00	98.00	119	141	-	-
Retained Earnings	-0.6%	-264	-262	-270	-266	-259	-251	-241	-228	-215	-204	-193	-176	-163	-144	-125	-105	-85.63	-59.57	-32.25	-	-
Additional Paid-In Capital	0.0%	276	276	275	270	270	268	267	265	263	261	258	225	223	220	192	187	183	179	173	-	-
Shares Outstanding	1.2%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	7.00	-	-	-	19.00	-	-	-	132	-	-	-	160	-	-	-	306	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	77.8%	-1,541	-6,935	-6,555	-6,214	-7,043	-9,915	-10,818	-12,835	-8,630	-7,923	-5,509	-14,455	-14,041	-15,048	-14,221	-29,180	-22,163	-23,812	-21,969	-34,271	-23,152
Share Based Compensation	-35.2%	103	159	379	426	1,124	1,662	1,699	1,767	2,547	2,412	2,340	2,312	3,207	3,796	3,953	4,036	4,470	4,948	6,224	3,989	3,609
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-7.00	2.00	1,462	1,436	3.00	-65.00	-1,356	-100	-554	-4,247	-1,814	-1,816
Cashflow From Financing	-	-	-	-	-	12.00	-	17.00	-	85.00	43.00	30,630	27.00	159	24,267	3,663	1.00	145	365	174,976	36,085	24,968

CYCN Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues [Abstract]
Revenue from development agreement	$ 0	$ 297
Total revenues	0	297
Cost and expenses:
Research and development	1,515	5,979
General and administrative	8,132	12,858
Impairment Loss	3,304	0
Total cost and expenses	12,951	18,837
Loss from operations	(12,951)	(18,540)
Interest and other income, net	358	294
Net loss from continuing operations	(12,593)	(18,246)
Discontinued operations:
Gain (loss) from discontinued operations	7,330	(25,832)
Net loss	$ (5,263)	$ (44,078)
*Net income (loss) per share - basic and diluted ()**
Net loss per share from continuing operations, basic	$ (5.39)	$ (8.4)
Income Loss from Discontinued Operations Basic	3.14	(11.89)
Basic net gain (loss) per share	(2.25)	(20.28)
Net loss per share from continuing operations, diluted	(5.39)	(8.4)
Income Loss from Discontinued Operations Diluted	3.14	(11.89)
Diluted net gain (loss) per share	$ (2.25)	$ (20.28)
Weighted average shares used in calculating:
Weighted Average Number of Shares Outstanding, Basic	2,338	2,173
Weighted Average Number of Shares Outstanding, Diluted	2,338	2,173
Other comprehensive loss:
Net loss	$ (5,263)	$ (44,078)
Other comprehensive loss:
Foreign currency translation adjustment gain	8	3
Comprehensive loss	$ (5,255)	$ (44,075)

CYCN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 7,571	$ 13,382
Accounts receivable	0	96
Prepaid expenses	442	805
Other current assets	11	537
Total current assets	8,024	14,820
Operating lease right-of-use asset	0	1,218
Other investment	5,350	0
Other assets	0	2,041
Total assets	13,374	18,079
Current liabilities:
Accounts payable	1,198	2,970
Accrued research and development costs	90	2,275
Accrued expenses and other current liabilities	798	2,382
Total current liabilities	2,086	7,627
Commitments and contingencies (Note 8)	0	0
Stockholders' equity
Preferred shares, no par value, 500,000 shares authorized and 351,037 series A convertible preferred stock issued and outstanding at December 31, 2023	0	0
Common stock, no par value, 20,000,000 shares authorized at December 31,2023 and 2022;2,645,096 and 2,175,936 shares issued at December 31,2023 and 2022, respectively; 2,474,159 and 2,175,936 shares outstanding at December 31,2023, and 2022, respectively	0	0
Paid-in capital	275,717	269,626
Accumulated deficit	(264,417)	(259,154)
Accumulated other comprehensive loss	(12)	(20)
Total stockholders' equity	11,288	10,452
Total liabilities and stockholders' equity	$ 13,374	$ 18,079

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018, a CNS-targeted sGC stimulator that is in preclinical trial for the treatment of neuropsychiatric diseases and disorders. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Peter M. Hecht Ph.D.
WEBSITE	cyclerion.com
INDUSTRY	Biotechnology
EMPLOYEES	16

Cyclerion Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Cyclerion Therapeutics Inc? What does CYCN stand for in stocks?

CYCN is the stock ticker symbol of Cyclerion Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cyclerion Therapeutics Inc (CYCN)?

As of Fri Apr 26 2024, market cap of Cyclerion Therapeutics Inc is 7.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYCN stock?

You can check CYCN's fair value in chart for subscribers.

What is the fair value of CYCN stock?

You can check CYCN's fair value in chart for subscribers. The fair value of Cyclerion Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cyclerion Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CYCN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cyclerion Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CYCN is over valued or under valued. Whether Cyclerion Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cyclerion Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYCN.

What is Cyclerion Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, CYCN's PE ratio (Price to Earnings) is -1.51 and Price to Sales (PS) ratio is 1.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYCN PE ratio will change depending on the future growth rate expectations of investors.